Medically reviewed on August 12, 2018
(es tra MUS teen)
- Estramustine Phosphate
- Estramustine Phosphate Sodium
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Capsule, Oral, as phosphate sodium:
Emcyt: 140 mg
Brand Names: U.S.
- Antineoplastic Agent, Alkylating Agent
- Antineoplastic Agent, Antimicrotubular
- Antineoplastic Agent, Hormone (Estrogen/Nitrogen Mustard)
Estramustine is an estradiol and nornitrogen mustard carbamate-linked combination which has antiandrogen effects (due to estradiol) and antimicrotubule effects (due to nornitrogen mustard); it causes a marked decrease in plasma testosterone and an increase in estrogen levels.
Incomplete (Bergenheim 1998)
Initially dephosphorylated in the GI tract, then hepatically oxidated and hydrolyzed to estramustine, estromustine (oxidized isomer of estramustine), estrone, and estradiol.
Feces (primarily); urine (trace amounts) (Bergenheim 1998)
Time to Peak
2 to 3 hours (Bergenheim 1998)
Estromustine: 13.6 hours (range: 9 to 23 hours); Estrone: 16.5 hours (Bergenheim 1998)
Special Populations: Hepatic Function Impairment
Estramustine may be poorly metabolized in patients with hepatic impairment.
Hypersensitivity to estramustine, estradiol, nitrogen mustard, or any component of the formulation; active thrombophlebitis or thromboembolic disorders (except where tumor mass is the cause of thromboembolic disorder and the benefit may outweigh the risk)
Canadian labeling: Additional contraindications (not in the US labeling): Severe hepatic or cardiac disease
Documentation of allergenic cross-reactivity for estrogens is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.
Dosing: Renal Impairment
There are no dosage adjustments provided in the manufacturer's labeling; use with caution.
Dosing: Hepatic Impairment
There are no dosage adjustments provided in the manufacturer's labeling; use with caution (may be poorly metabolized).
Estramustine is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting.
Oral: Administer on an empty stomach, at least 1 hour before or 2 hours after eating. Administer with water; do not administer with milk, milk-based products, or calcium products.
Milk products and calcium-rich foods or supplements may impair the oral absorption of estramustine phosphate sodium.
Store at 2°C to 8°C (36°F to 46°F).
Baricitinib: Immunosuppressants may enhance the immunosuppressive effect of Baricitinib. Management: Use of baricitinib in combination with potent immunosuppressants such as azathioprine or cyclosporine is not recommended. Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted. Consider therapy modification
BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). Avoid combination
Calcium Salts: May decrease the absorption of Estramustine. Exceptions: Calcium Chloride. Consider therapy modification
Clodronate: May increase the serum concentration of Estramustine. Monitor therapy
Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. Monitor therapy
Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased. Monitor therapy
Echinacea: May diminish the therapeutic effect of Immunosuppressants. Consider therapy modification
Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod. Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections). Consider therapy modification
Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants. Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly. Consider therapy modification
Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim. Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy. Consider therapy modification
Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim. Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy. Consider therapy modification
Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. Avoid combination
Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. Consider therapy modification
Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants. Monitor therapy
Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy. Consider therapy modification
Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. Monitor therapy
Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants. Avoid combination
Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants. Consider therapy modification
Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. Monitor therapy
Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants. Avoid combination
Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. Monitor therapy
Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib. Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants. Consider therapy modification
Trastuzumab: May enhance the neutropenic effect of Immunosuppressants. Monitor therapy
Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation. Consider therapy modification
Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants. Avoid combination
Frequency not always defined.
Cardiovascular: Edema (20%)
Endocrine & metabolic: Gynecomastia (75%), increased lactate dehydrogenase (2% to 33%), decreased libido
Gastrointestinal: Nausea (16%), diarrhea (13%), gastrointestinal irritation (12%)
Genitourinary: Breast tenderness (71%)
Hepatic: Increased serum AST (2% to 33%)
Respiratory: Dyspnea (12%)
1% to 10%:
Cardiovascular: Cardiac failure (3%), local thrombophlebitis (3%), myocardial infarction (3%), cerebrovascular accident (2%), pulmonary embolism (2%), chest pain (1%), flushing (1%)
Central nervous system: Lethargy (4%), insomnia (3%), emotional lability (2%), anxiety (1%), headache (1%)
Dermatologic: Pruritus (2%), xeroderma (2%), exfoliation of skin (1%), skin rash (1%), thinning hair (1%)
Endocrine & metabolic: Increased thirst (1%)
Gastrointestinal: Anorexia (4%), flatulence (2%), gastrointestinal hemorrhage (1%), sore throat (1%), vomiting (1%)
Hematologic & oncologic: Leukopenia (4%), bruise (3%), thrombocytopenia (1%)
Hepatic: Increased serum bilirubin (1% to 2%)
Neuromuscular & skeletal: Leg cramps (9%)
Ophthalmic: Lacrimation (1%)
Respiratory: Hoarseness (1%), rhinorrhea (1%)
<1%, postmarketing, and/or case reports: Anemia, angina pectoris, angioedema, cerebral ischemia, confusion, depression, decreased glucose tolerance, hypercalcemia, hypocalcemia, hypersensitivity reaction, hypertension, impotence, ischemic heart disease, myasthenia, venous thrombosis
Concerns related to adverse effects:
• Cardiovascular effects: Elevated blood pressure or congestive heart disease may occur. Estrogen treatment for prostate cancer is associated with an increased risk of thrombosis or MI (including fatalities). Use with caution in patients with a history of thrombophlebitis, thrombosis, or thromboembolic disease, especially if associated with estrogen therapy. Use with caution in patients with cerebrovascular disease or coronary artery disease.
• Endocrine effects: Estrogenic effects may decrease testosterone levels; may cause gynecomastia and/or impotence.
• Fluid retention: Peripheral edema (new onset or exacerbation) or congestive heart disease has been observed. Use with caution in patients where fluid accumulation may be poorly tolerated, including cardiovascular disease (HF or hypertension), migraine, seizure disorder or renal dysfunction.
• Gastrointestinal toxicity: Estramustine is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting.
• Glucose tolerance: Glucose tolerance may be decreased; use with caution in patients with diabetes mellitus.
• Hepatic effects: Liver enzyme and bilirubin abnormalities may occur; monitor during and for 2 months after treatment.
• Hypersensitivity: Allergic reactions and angioedema, including airway involvement, have been reported.
• Hypertension: May cause hypertension; monitor blood pressure periodically.
• Hepatic impairment: Use with caution in patients with hepatic impairment (estramustine may be metabolized poorly).
• Metabolic bone disease: Use with caution in patients with metabolic bone diseases (due to the effects on calcium and phosphorus homeostasis).
• Osteoblastic metastases: Patients with osteoblastic metastases are at risk for hypocalcemia; monitor calcium regularly.
• Renal impairment: Use with caution in patients with renal impairment.
Concurrent drug therapy issues:
• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.
• Limitation of use: A clinical practice guideline from the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario recommends that estramustine not be offered to men with metastatic castration-resistant prostate cancer due to a lack of benefit in survival or quality of life (ASCO [Basch 2014]).
Monitor serum calcium, liver function tests (during and for 2 months following treatment), and serum glucose (in diabetic patients). Monitor blood pressure and fluid status. Monitor adherence.
Estramustine is not indicated for use in women. Some men who were impotent on estrogen therapy have regained potency while taking estramustine; effective contraception should be used for male patients with partners of childbearing potential.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience nausea, vomiting, diarrhea, leg cramps, breast pain or soreness, enlarged breasts, or sexual dysfunction. Have patient report immediately to prescriber signs of high blood sugar (confusion, fatigue, increased thirst, increased hunger, polyuria, flushing, fast breathing, or breath that smells like fruit), signs of severe cerebrovascular disease (change in strength on one side is greater than the other, difficulty speaking or thinking, change in balance, or vision changes), signs of DVT (edema, warmth, numbness, change in color, or pain in the extremities), angina, tachycardia, severe dizziness, passing out, shortness of breath, excessive weight gain, swelling of arms or legs, severe headache, coughing up blood, or vision changes (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about estramustine
- Estramustine Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Support Group
- En Español
- 0 Reviews
- Drug class: hormones/antineoplastics
Other brands: Emcyt